secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001558370-24-015838
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO
--------------------------------------------------------------------------------

- License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.
- Private placement: 35.6M shares at $2.25 for $80M gross; closed Nov 19; led by Vivo Capital; cash runway into 2028.
- Leadership additions: Hugh Davis as President/COO + Class III director; Steven Knapp EVP Regulatory & Quality.
- Adopted 2024 Inducement Plan reserving 2M shares; Davis granted options for 375K shares, RSU for 107K shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/acrs-20241116x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer